Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (19 quarters reported)
$295M in Q4 2021 → $189M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| AI Alphabet Inc-cl C | 17.1% | Unchanged | 91,420 | $32.3M |
| Apollo Global Management, Inc. | 14.1% | Unchanged | 225,000 | $26.6M |
| SP Syndax Pharmaceutical, Inc. | 5.1% | Added 3.6% | 437,245 | $9.56M |
| Xeris Biopharma Holdings, Inc. | 4.4% | Unchanged | 1,060,000 | $8.4M |
| Travere Therapeutics, Inc. | 4.4% | Added 4.7% | 147,282 | $8.37M |
| Protagonist Therapeutics, Inc | 4.1% | Unchanged | 63,000 | $7.72M |
| Bridgebio Pharma, Inc. | 3.7% | Added 3.2% | 92,850 | $6.92M |
| Iovance Biotherapeutics, Inc. | 3.5% | Unchanged | 1,600,000 | $6.66M |
| Alkermes PLC | 3.4% | Added 1.5% | 121,759 | $6.38M |
| Jpmorgan Chase & Co. | 3.1% | Trimmed 7.1% | 18,098 | $5.92M |
| JH Janus Henderson Aaa Clo ETF | 2.5% | Unchanged | 93,528 | $4.72M |
| Lpl Financial Holdings Inc. | 2.5% | Unchanged | 16,500 | $4.65M |
| Cogent Biosciences Inc. | 2.3% | Added 6.8% | 111,081 | $4.3M |
| Tg Therapeutics, Inc. | 1.9% | Trimmed 26% | 66,839 | $3.67M |
| Catalyst Pharmaceuticals, Inc. | 1.9% | New | 114,000 | $3.58M |
| AP Agios Pharmaceutical, Inc. | 1.9% | Added 2.1% | 95,058 | $3.53M |
| Viridian Therapeutics, Inc. | 1.8% | Unchanged | 181,000 | $3.32M |
| Relmada Therapeutics, Inc. | 1.6% | Added 2.7% | 451,000 | $3.12M |
| Arcus Biosciences, Inc. | 1.3% | Unchanged | 81,241 | $2.5M |
| Cybin Inc | 1.3% | Added 5.7% | 370,000 | $2.45M |
| SS SPDR S&P Biotech ETF | 1.3% | Unchanged | 15,000 | $2.37M |
| Rezolute, Inc. | 1.0% | Unchanged | 370,000 | $1.92M |
| AH Alliancebernstein Holding L.p. | 0.9% | Unchanged | 48,000 | $1.69M |
| MP Madrigal Pharmaaceuticals, Inc. | 0.9% | Added 50% | 3,000 | $1.61M |
| Atricure, Inc. | 0.8% | Unchanged | 51,400 | $1.44M |
| Docgo, Inc. | 0.7% | Unchanged | 2,670,850 | $1.38M |
| Ardelyx, Inc. | 0.7% | Added 27% | 263,168 | $1.34M |
| Ultragenyx Pharmaceutical Inc. | 0.7% | Added 15% | 38,069 | $1.27M |
| PB The Panagram Bbb-b Clo ETF | 0.7% | Unchanged | 47,807 | $1.26M |
| Cullinan Therapeutics, Inc. | 0.7% | Added 186% | 69,182 | $1.26M |
| Johnson & Johnson | 0.7% | Unchanged | 4,922 | $1.25M |
| Vera Therapeutics, Inc. | 0.6% | Unchanged | 26,000 | $1.12M |
| Orchestra Biomed Holdings, Inc. | 0.6% | Unchanged | 253,651 | $1.09M |
| Spruce Biosciences, Inc. | 0.6% | New | 20,000 | $1.08M |
| Connect Biopharma Holdings Limited | 0.6% | Added 15% | 444,862 | $1.06M |
| IB Ishares Biotechnology ETF | 0.6% | Unchanged | 5,500 | $1.05M |
| Biogen Inc. | 0.5% | Unchanged | 4,000 | $864K |
| Pfizer Inc. | 0.4% | Unchanged | 32,337 | $779K |
| Apple Inc. | 0.4% | Unchanged | 2,494 | $722K |
| Canadian Natural Resources Limited | 0.4% | Unchanged | 16,800 | $664K |
| Pelthos Therapeutics, Inc. | 0.3% | Added 4.7% | 22,073 | $624K |
| International Business Machines | 0.3% | Unchanged | 2,142 | $602K |
| Microsoft Corporation | 0.3% | Unchanged | 1,600 | $597K |
| Verastem Inc. | 0.3% | Added 49% | 155,000 | $592K |
| Kura Oncology, Inc. | 0.3% | Unchanged | 52,767 | $579K |
| SB Solid Bioscience Inc. | 0.3% | Added 19% | 56,208 | $562K |
| Dupont De Nemours, Inc. | 0.3% | New | 3,767 | $511K |
| Insmed Incorporated | 0.2% | New | 4,253 | $453K |
| Lb Pharmaceuticals, Inc. | 0.2% | New | 12,965 | $421K |
| Caredx, Inc. | 0.2% | New | 13,630 | $388K |
| Q32 Bio Inc | 0.2% | New | 30,412 | $387K |
| Enliven Therapeutics, Inc. | 0.2% | New | 6,183 | $314K |
| Ryman Hospitality Properties, Inc. | 0.2% | Unchanged | 2,400 | $309K |
| Broadcom, Inc. | 0.1% | Unchanged | 710 | $268K |
| Kimberly-clark Corporation | 0.1% | Unchanged | 2,400 | $263K |
| Nvidia Corp | 0.1% | Unchanged | 1,280 | $256K |
| Boston Scientific Corporation | 0.1% | New | 6,000 | $256K |
| WL Wave Life Science Ltd. | 0.1% | Unchanged | 40,000 | $232K |
| Rain Enhancement Technologies Holdco Inc | 0.1% | Unchanged | 101,686 | $210K |
| Mondelez International, Inc. | 0.1% | Unchanged | 3,000 | $174K |
Showing top 60 of 84 positions.
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 12, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Catalyst Pharmaceuticals, Inc. | New | +114,000 | +$3.58M | 1.9% |
| Catalyst Pharmaceuticals, Inc. | Exited | −120,000 | −$2.97M | — |
| Arcellx Inc | Exited | −19,433 | −$2.23M | — |
| Cytokinetics, Incorporated | Exited | −23,644 | −$1.56M | — |
| Centessa Pharmaceuticals PLC | Exited | −39,000 | −$1.55M | — |
| Tg Therapeutics, Inc. | Trimmed | −23,162 | −$1.27M | 1.9% |
| Spruce Biosciences, Inc. | New | +20,000 | +$1.08M | 0.6% |
| Cullinan Therapeutics, Inc. | Added | +44,982 | +$819K | 0.7% |
| Bristol-myers Squibb Company | Trimmed | −11,622 | −$670K | 0.1% |
| Adma Biologics, Inc. | Exited | −60,200 | −$542K | — |
Showing the 10 largest of 43 changes.
quarter ended March 31, 2026 · filed May 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Calumet, Inc. | Exited | −2,214,969 | −$44M | — |
| Iovance Biotherapeutics, Inc. | New | +1,600,000 | +$5.62M | 3.3% |
| Lpl Financial Holdings Inc. | New | +16,500 | +$4.96M | 3.0% |
| Relmada Therapeutics, Inc. | New | +439,300 | +$3.06M | 1.8% |
| AP Agios Pharmaceutical, Inc. | Added | +75,058 | +$2.54M | 1.9% |
| Catalyst Pharmaceuticals, Inc. | Trimmed | −69,000 | −$1.71M | 1.8% |
| Tectonic Therapeutic, Inc. | Exited | −74,000 | −$1.54M | — |
| Tg Therapeutics, Inc. | Added | +45,001 | +$1.49M | 1.8% |
| Centessa Pharmaceuticals PLC | Added | +35,000 | +$1.39M | 0.9% |
| Travere Therapeutics, Inc. | Trimmed | −45,367 | −$1.35M | 2.5% |
Showing the 10 largest of 52 changes.
quarter ended December 31, 2025 · filed February 12, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| JH Janus Henderson Aaa Clo ETF | Trimmed | −344,226 | −$17.4M | 2.2% |
| Calumet, Inc. | Trimmed | −610,262 | −$12.1M | 20.4% |
| Darling Ingredients Inc. | Exited | −300,000 | −$9.26M | — |
| AI Alphabet Inc-cl C | Trimmed | −20,800 | −$6.53M | 13.3% |
| Avadel Pharmaceuticals PLC | Exited | −363,000 | −$5.54M | — |
| Verona Pharma Plc. | Exited | −38,355 | −$4.09M | — |
| Cogent Biosciences Inc. | New | +102,000 | +$3.62M | 1.7% |
| Travere Therapeutics, Inc. | Trimmed | −74,000 | −$2.83M | 3.3% |
| Csx Corporation | Exited | −70,000 | −$2.48M | — |
| Liquidia Corporation | Exited | −107,783 | −$2.45M | — |
Showing the 10 largest of 62 changes.
quarter ended September 30, 2025 · filed November 12, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Darling Ingredients Inc. | New | +300,000 | +$9.26M | 3.7% |
| Calumet, Inc. | Trimmed | −450,000 | −$8.21M | 20.8% |
| JH Janus Henderson Aaa Clo ETF | Trimmed | −57,500 | −$2.92M | 9.0% |
| Inozyme Pharma, Inc. | Exited | −666,204 | −$2.66M | — |
| Rezolute, Inc. | New | +275,000 | +$2.59M | 1.0% |
| Enstar Group Limited | Exited | −7,500 | −$2.52M | — |
| Biocryst Pharmaceuticals, Inc. | Trimmed | −300,055 | −$2.28M | 0.1% |
| Arcellx Inc | New | +25,700 | +$2.11M | 0.9% |
| Verona Pharma Plc. | Trimmed | −16,645 | −$1.78M | 1.7% |
| Arcellx Inc | Exited | −25,700 | −$1.69M | — |
Showing the 10 largest of 53 changes.
quarter ended June 30, 2025 · filed August 11, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Pfizer Inc. | Trimmed | −180,000 | −$4.36M | 0.8% |
| Bridgebio Pharma, Inc. | New | +80,000 | +$3.45M | 1.6% |
| Verona Pharma Plc. | Trimmed | −33,000 | −$3.12M | 2.4% |
| JH Janus Henderson Aaa Clo ETF | Trimmed | −56,509 | −$2.87M | 11.4% |
| Ardelyx, Inc. | Exited | −493,807 | −$2.42M | — |
| Lenz Therapeutics, Inc. | New | +82,000 | +$2.4M | 1.1% |
| Omniab, Inc. | Exited | −982,336 | −$2.36M | — |
| SP Syndax Pharmaceutical, Inc. | Added | +224,778 | +$2.11M | 1.5% |
| IA The Invesco Aaa Floating Rate Note ETF | Exited | −70,502 | −$1.8M | — |
| Arcellx Inc | New | +25,700 | +$1.69M | 0.8% |
Showing the 10 largest of 48 changes.
quarter ended March 31, 2025 · filed May 12, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| JH Janus Henderson Aaa Clo ETF | Exited | −157,932 | −$8.01M | — |
| Verona Pharma Plc. | Trimmed | −71,300 | −$4.53M | 2.6% |
| Calumet, Inc. | Trimmed | −354,167 | −$4.49M | 19.7% |
| IA The Invesco Aaa Floating Rate Note ETF | Trimmed | −130,985 | −$3.34M | 0.8% |
| JH Janus Henderson Aaa Clo ETF | Trimmed | −38,634 | −$1.96M | 13.2% |
| Ultragenyx Pharmaceutical Inc. | New | +48,000 | +$1.74M | 0.8% |
| Viking Therapeutics, Inc. | Exited | −39,036 | −$1.57M | — |
| Myriad Genetics, Inc. | New | +160,000 | +$1.42M | 0.7% |
| Cogent Biosciences Inc. | New | +213,302 | +$1.28M | 0.6% |
| Regeneron Pharmaceuticals, Inc. | New | +2,000 | +$1.27M | 0.6% |
Showing the 10 largest of 59 changes.
quarter ended December 31, 2024 · filed February 12, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| JH Janus Henderson Aaa Clo ETF | Added | +505,568 | +$25.6M | 10.8% |
| Calumet, Inc. | Trimmed | −673,639 | −$14.8M | 29.1% |
| PB The Panagram Bbb-b Clo ETF | Trimmed | −495,061 | −$13.3M | 0.5% |
| JH Janus Henderson Aaa Clo ETF | New | +157,932 | +$8.01M | 2.9% |
| MF Medical Facilities Corp | Exited | −534,207 | −$5.33M | — |
| Avadel Pharmaceuticals PLC | Exited | −332,000 | −$4.35M | — |
| Avadel Pharmaceuticals PLC | New | +346,904 | +$3.65M | 1.3% |
| Gsk PLC | Exited | −65,000 | −$2.66M | — |
| Digimarc Corporation | Exited | −83,557 | −$2.25M | — |
| BP Biomarin Phamaceutical Inc. | Trimmed | −28,200 | −$1.85M | 0.1% |
Showing the 10 largest of 40 changes.
quarter ended September 30, 2024 · filed November 13, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| CS Calumet Specialty Products Partners, LP | New | +4,325,000 | +$77.1M | 27.1% |
| CS Calumet Specialty Products Partners, LP | Exited | −4,325,000 | −$69.4M | — |
| Ligand Pharmaceuticals Incorporated | Exited | −85,000 | −$7.16M | — |
| BP Biomarin Pharmaceuticals Inc. | New | +34,000 | +$2.39M | 0.8% |
| Viking Therapeutics, Inc. | Trimmed | −37,000 | −$2.34M | 0.9% |
| Luckin Coffee, Inc | Exited | −100,000 | −$2.11M | — |
| JH Janus Henderson Aaa Clo ETF | Added | +31,432 | +$1.6M | 1.5% |
| JH Janus Henderson Aaa Clo ETF | Exited | −31,432 | −$1.6M | — |
| IA The Invesco Aaa Floating Rate Note ETF | Trimmed | −48,866 | −$1.25M | 1.7% |
| Evolus, Inc. | Trimmed | −51,112 | −$828K | 0.3% |
Showing the 10 largest of 61 changes.
Loading...
